Affinity Asset Advisors, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 14, 2026), Affinity Asset Advisors, LLC reported 90 stock positions worth $1.7 billion. Its top holding was Apogee Therapeutics (APGE) at 6.5% of the portfolio, followed by Xenon Pharmaceuticals (XENE, 5.8%) and Erasca (ERAS, 5.2%). Compared with Q4 2025, it opened 20 new positions, sold out of 10, added to 30 and reduced 24. The biggest buy was Erasca (ERAS, shares +37%) and the biggest sale an exit from Ventyx Biosciences (VTYX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $1.7B (Q1 2026)
- SEC Filing
- 0001315863-26-000411 ↗ filed May 14, 2026
Holdings Value
Holdings 90 stocks · $1.7B
| APGE Apogee Therapeutics Inc. | 6.47% | 1,284,926 | $108.2M | Add +4.0% |
| XENE Xenon Pharmaceuticals Inc. | 5.83% | 1,675,000 | $97.4M | Add +34.0% |
| ERAS Erasca Inc. | 5.18% | 5,350,000 | $86.6M | Add +37.2% |
| INSM Insmed Inc. | 4.70% | 480,000 | $78.5M | Add +6.7% |
| ROIV Roivant Sciences Ltd. | 4.64% | 2,800,000 | $77.6M | Add +64.7% |
| SYRE Spyre Therapeutics Inc. | 3.86% | 1,279,134 | $64.5M | Reduce -10.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.33% | 1,400,000 | $55.6M | Add +133.1% |
| PRAX Praxis Precision Medicines I | 3.28% | 170,000 | $54.8M | Reduce -8.1% |
| ANAB Anaptysbio Inc. | 3.12% | 940,000 | $52.1M | Add +111.4% |
| ALKS Alkermes PLC | 2.86% | 1,350,000 | $47.7M | Add +35.0% |
| CYTK Cytokinetics Inc. | 2.76% | 700,483 | $46.2M | Reduce -12.4% |
| ABVX Abivax SA-ADR | 2.70% | 405,000 | $45.1M | Reduce -19.8% |
| TEVA Teva Pharmaceutical-SP ADR | 2.52% | 1,400,000 | $42.2M | No change |
| ACLX Arcellx Inc. | 2.49% | 362,764 | $41.7M | Reduce -30.7% |
| NUVL Nuvalent Inc. Class A | 1.84% | 300,000 | $30.7M | Reduce -7.0% |
| TERN Terns Pharmaceuticals Inc. | 1.77% | 562,631 | $29.7M | Add +2.3% |
| DNTH Dianthus Therapeutics Inc. | 1.76% | 350,000 | $29.4M | Add +204.3% |
| LXEO Lexeo Therapeutics Inc. | 1.73% | 5,050,211 | $29.0M | Add +57.8% |
| COGT Cogent Biosciences Inc. | 1.73% | 750,000 | $28.9M | Add +114.3% |
| MDGL Madrigal Pharmaceuticals Inc. | 1.72% | 55,000 | $28.8M | Add +76.7% |
| STRO Sutro Biopharma Inc. | 1.59% | 1,069,519 | $26.6M | Add +42.9% |
| FBRX Forte Biosciences Inc. | 1.57% | 1,011,890 | $26.2M | Add +2.3% |
| ORKA Oruka Therapeutics Inc. | 1.47% | 499,673 | $24.5M | Reduce -37.7% |
| TRVI Trevi Therapeutics Inc. | 1.43% | 2,000,172 | $23.9M | Reduce -7.0% |
| OVID Ovid Therapeutics Inc. | 1.41% | 10,636,318 | $23.6M | Add +48.8% |
| ELVN Enliven Therapeutics Inc. | 1.38% | 586,904 | $23.0M | New |
| ASND Ascendis Pharma A/S | 1.30% | 95,000 | $21.7M | Add +216.7% |
| MLYS Mineralys Therapeutics Inc. | 1.22% | 750,000 | $20.3M | Add +2.7% |
| AVTX Avalo Therapeutics Inc. | 1.20% | 1,340,840 | $20.0M | Add +27.6% |
| PTGX Protagonist Therapeutics Inc. | 1.09% | 172,125 | $18.1M | No change |
| CLDX Celldex Therapeutics Inc. | 0.95% | 500,000 | $15.9M | Add +42.9% |
| ZURA Zura Bio Ltd. | 0.91% | 2,564,303 | $15.3M | Add +41.4% |
| NRIX Nurix Therapeutics Inc. | 0.90% | 967,620 | $15.0M | No change |
| SVRA Savara Inc. | 0.82% | 2,512,153 | $13.7M | Reduce -10.2% |
| CATX Perspective Therapeutics Inc. | 0.79% | 3,164,582 | $13.2M | Add +954.9% |
| HLXC Helix Acquisition Corp. Class A | 0.76% | 1,250,000 | $12.7M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.75% | 200,000 | $12.5M | Add +185.7% |
| DMRA Damora Therapeutics Inc. | 0.70% | 450,000 | $11.7M | New |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.69% | 1,589,005 | $11.5M | Add +429.7% |
| ANRO Alto Neuroscience Inc. | 0.67% | 500,000 | $11.2M | New |
| BBIO Bridgebio Pharma Inc. | 0.67% | 150,000 | $11.1M | Reduce -53.1% |
| CGEM Cullinan Therapeutics Inc. | 0.66% | 781,260 | $11.1M | Reduce -59.6% |
| BLTE Belite Bio Inc. - ADR | 0.62% | 65,000 | $10.4M | Add +225.0% |
| WVE Wave Life Sciences Ltd. | 0.61% | 1,401,727 | $10.2M | Reduce -48.1% |
| VERA Vera Therapeutics Inc. | 0.60% | 250,000 | $10.1M | No change |
| TYRA Tyra Biosciences Inc. | 0.59% | 257,512 | $9.9M | New |
| RVMD Revolution Medicines Inc. | 0.58% | 100,000 | $9.7M | No change |
| JBIO Jade Biosciences Inc. | 0.54% | 639,956 | $9.0M | Reduce -10.5% |
| TVTX Travere Therapeutics Inc. | 0.53% | 300,000 | $8.9M | No change |
| NAMS Newamsterdam Pharma Co. NV | 0.53% | 275,000 | $8.8M | No change |
| KRRO Korro Bio Inc. | 0.48% | 706,904 | $8.0M | New |
| CRSP Crispr Therapeutics AG | 0.43% | 150,000 | $7.1M | New |
| SGP Spyglass Pharma Inc. | 0.39% | 250,000 | $6.5M | New |
| CMPS Compass Pathways PLC | 0.37% | 1,108,483 | $6.1M | Add +454.2% |
| IBIO Ibio Inc. | 0.35% | 3,107,200 | $5.9M | Add +51.0% |
| ESTA Establishment Labs Holdings | 0.34% | 100,000 | $5.7M | Reduce -50.0% |
| AVR Anteris Technologies Global | 0.30% | 912,397 | $5.1M | Add +87.5% |
| VRDN Viridian Therapeutics Inc. | 0.29% | 250,000 | $4.9M | No change |
| CLYM Climb Bio Inc. | 0.29% | 700,000 | $4.8M | Reduce -46.1% |
| RZLT Rezolute Inc. | 0.28% | 1,547,641 | $4.7M | Reduce -34.2% |
| SGMT Sagimet Biosciences Inc. Class A | 0.27% | 868,020 | $4.5M | Reduce -24.4% |
| MBX MBX Biosciences Inc. | 0.27% | 150,000 | $4.5M | Reduce -40.0% |
| TSHA Taysha Gene Therapies Inc. | 0.27% | 1,000,000 | $4.5M | Reduce -69.7% |
| MANE Veradermics Inc. | 0.26% | 70,000 | $4.4M | New |
| GENB Generate Biomedicines Inc. | 0.26% | 350,000 | $4.4M | New |
| ENGN Engene Holdings Inc. | 0.25% | 610,370 | $4.2M | Reduce -5.1% |
| AVBP Arrivent Biopharma Inc. | 0.24% | 175,000 | $4.0M | Add +16.7% |
| RLAY Relay Therapeutics Inc. | 0.24% | 400,000 | $4.0M | New |
| PRQR Proqr Therapeutics NV | 0.24% | 2,454,278 | $4.0M | No change |
| VRCA Verrica Pharmaceuticals Inc. | 0.22% | 707,338 | $3.7M | No change |
| DTIL Precision Biosciences Inc. | 0.20% | 597,946 | $3.3M | New |
| KPTI Karyopharm Therapeutics Inc. | 0.17% | 500,000 | $2.8M | Reduce -43.8% |
| SLGL Sol-Gel Technologies Ltd. | 0.17% | 35,000 | $2.8M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 0.16% | 75,000 | $2.7M | No change |
| OACCU Oaktree Acquisition III Life | 0.16% | 250,000 | $2.7M | No change |
| NXTC Nextcure Inc. | 0.15% | 241,826 | $2.6M | Reduce -2.2% |
| IMVT Immunovant Inc. | 0.15% | 100,000 | $2.5M | Reduce -50.0% |
| EQ Equillium Inc. | 0.15% | 1,226,310 | $2.5M | New |
| SABS Sab Biotherapeutics Inc. | 0.13% | 575,000 | $2.2M | New |
| CORT Corcept Therapeutics Inc. | 0.12% | 50,000 | $2.0M | New |
| OBIO Orchestra Biomed Holdings Inc. | 0.10% | 402,550 | $1.7M | Reduce -29.7% |
| KZR Kezar Life Sciences Inc. | 0.10% | 229,076 | $1.7M | No change |
| MGNX Macrogenics Inc. | 0.09% | 500,000 | $1.4M | Add +3.2% |
| ANL Adlai Nortye Group Ltd. | 0.07% | 164,748 | $1.1M | New |
| ALEC Alector Inc. | 0.06% | 500,000 | $1.1M | New |
| OKUR Onkure Therapeutics Inc. Class A | 0.06% | 240,963 | $998K | New |
| LENZ Lenz Therapeutics Inc. | 0.05% | 100,000 | $915K | New |
| XFOR X4 Pharmaceuticals Inc. | 0.04% | 145,000 | $599K | No change |
| QTTB Q32 Bio Inc. | 0.01% | 27,777 | $178K | No change |
| ADGM Adagio Medical Holdings Inc. | 0.01% | 80,000 | $92K | No change |
Options reported separately and not counted above: SPY puts ($130.1M), MRNA calls ($40.6M), BMY calls ($18.2M), RVMD puts ($9.7M), IBRX puts ($9.6M), NVO calls ($6.4M), QURE calls ($4.9M), DNTH calls ($4.2M), CGON calls ($4.1M), CELC calls ($3.4M).
Other holdings (5): bonds, preferreds, convertibles and warrants · $34.0M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| OMEROS CORP (OMER 9.5 06/15/29) | NOTE 9.500% 6/1 · principal | 6,525,000 | $13.2M | No change |
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | 7,000,000 | $8.6M | Add +600.0% |
| CELCUITY INC (CELC 2.75 08/01/31) | NOTE 2.750% 8/0 · principal | 3,000,000 | $7.3M | No change |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 245,000 | $4.9M | No change |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $1K | No change |
Total filed on the 13F, all lines: $1.7B.
Portfolio Sells Q4 2025 → Q1 2026
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −4.34 |
| WVE Wave Life Sciences Ltd. | Reduce -48.1% | 0.61% | −2.79 |
| ABVX Abivax SA-ADR | Reduce -19.8% | 2.70% | −2.35 |
| BBIO Bridgebio Pharma Inc. | Reduce -53.1% | 0.67% | −1.15 |
| TSHA Taysha Gene Therapies Inc. | Reduce -69.7% | 0.27% | −1.08 |
| CYTK Cytokinetics Inc. | Reduce -12.4% | 2.76% | −1.01 |
| CGEM Cullinan Therapeutics Inc. | Reduce -59.6% | 0.66% | −0.82 |
| PRAX Praxis Precision Medicines I | Reduce -8.1% | 3.28% | −0.76 |
| ESTA Establishment Labs Holdings | Reduce -50.0% | 0.34% | −0.74 |
| TNGX Tango Therapeutics Inc. | Sold out | 0.00% | −0.66 |
| TRVI Trevi Therapeutics Inc. | Reduce -7.0% | 1.43% | −0.57 |
| NUVL Nuvalent Inc. Class A | Reduce -7.0% | 1.84% | −0.57 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −0.53 |
| SVRA Savara Inc. | Reduce -10.2% | 0.82% | −0.43 |
| AVDL Avadel Pharmaceuticals Ltd. | Sold out | 0.00% | −0.40 |
| ORKA Oruka Therapeutics Inc. | Reduce -37.7% | 1.47% | −0.34 |
| KPTI Karyopharm Therapeutics Inc. | Reduce -43.8% | 0.17% | −0.32 |
| MBX MBX Biosciences Inc. | Reduce -40.0% | 0.27% | −0.32 |
| JBIO Jade Biosciences Inc. | Reduce -10.5% | 0.54% | −0.28 |
| AMGN Amgen Inc. | Sold out | 0.00% | −0.24 |
| SGMT Sagimet Biosciences Inc. Class A | Reduce -24.4% | 0.27% | −0.23 |
| IMVT Immunovant Inc. | Reduce -50.0% | 0.15% | −0.23 |
| MRSN Mersana Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| ENGN Engene Holdings Inc. | Reduce -5.1% | 0.25% | −0.18 |
| GERN Geron Corp. | Sold out | 0.00% | −0.15 |
| RZLT Rezolute Inc. | Reduce -34.2% | 0.28% | −0.13 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.13 |
| NXTC Nextcure Inc. | Reduce -2.2% | 0.15% | −0.11 |
| CLYM Climb Bio Inc. | Reduce -46.1% | 0.29% | −0.10 |
| QURE Uniqure NV | Sold out | 0.00% | −0.09 |
| OBIO Orchestra Biomed Holdings Inc. | Reduce -29.7% | 0.10% | −0.07 |
| FRNM Freenome Inc. | Sold out | 0.00% | −0.05 |
| ACLX Arcellx Inc. | Reduce -30.7% | 2.49% | −0.04 |
| SYRE Spyre Therapeutics Inc. | Reduce -10.7% | 3.86% | +0.38 |
Portfolio Buys Q4 2025 → Q1 2026
| ERAS Erasca Inc. | Add +37.2% | 5.18% | +4.10 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +133.1% | 3.33% | +2.21 |
| ROIV Roivant Sciences Ltd. | Add +64.7% | 4.64% | +1.91 |
| XENE Xenon Pharmaceuticals Inc. | Add +34.0% | 5.83% | +1.68 |
| ANAB Anaptysbio Inc. | Add +111.4% | 3.12% | +1.52 |
| DNTH Dianthus Therapeutics Inc. | Add +204.3% | 1.76% | +1.41 |
| ELVN Enliven Therapeutics Inc. | New | 1.38% | +1.38 |
| STRO Sutro Biopharma Inc. | Add +42.9% | 1.59% | +0.95 |
| ASND Ascendis Pharma A/S | Add +216.7% | 1.30% | +0.83 |
| COGT Cogent Biosciences Inc. | Add +114.3% | 1.73% | +0.81 |
| ALKS Alkermes PLC | Add +35.0% | 2.86% | +0.78 |
| HLXC Helix Acquisition Corp. Class A | New | 0.76% | +0.76 |
| CATX Perspective Therapeutics Inc. | Add +954.9% | 0.79% | +0.73 |
| DMRA Damora Therapeutics Inc. | New | 0.70% | +0.70 |
| ANRO Alto Neuroscience Inc. | New | 0.67% | +0.67 |
| TYRA Tyra Biosciences Inc. | New | 0.59% | +0.59 |
| OVID Ovid Therapeutics Inc. | Add +48.8% | 1.41% | +0.55 |
| EPRX Eupraxia Pharmaceuticals Inc. | Add +429.7% | 0.69% | +0.52 |
| KRRO Korro Bio Inc. | New | 0.48% | +0.48 |
| CRSP Crispr Therapeutics AG | New | 0.43% | +0.43 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +185.7% | 0.75% | +0.41 |
| SGP Spyglass Pharma Inc. | New | 0.39% | +0.39 |
| BLTE Belite Bio Inc. - ADR | Add +225.0% | 0.62% | +0.38 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +76.7% | 1.72% | +0.38 |
| CMPS Compass Pathways PLC | Add +454.2% | 0.37% | +0.26 |
| MANE Veradermics Inc. | New | 0.26% | +0.26 |
| GENB Generate Biomedicines Inc. | New | 0.26% | +0.26 |
| CLDX Celldex Therapeutics Inc. | Add +42.9% | 0.95% | +0.24 |
| RLAY Relay Therapeutics Inc. | New | 0.24% | +0.24 |
| ZURA Zura Bio Ltd. | Add +41.4% | 0.91% | +0.21 |
| DTIL Precision Biosciences Inc. | New | 0.20% | +0.20 |
| SLGL Sol-Gel Technologies Ltd. | New | 0.17% | +0.17 |
| EQ Equillium Inc. | New | 0.15% | +0.15 |
| SABS Sab Biotherapeutics Inc. | New | 0.13% | +0.13 |
| TERN Terns Pharmaceuticals Inc. | Add +2.3% | 1.77% | +0.13 |
| AVR Anteris Technologies Global | Add +87.5% | 0.30% | +0.12 |
| CORT Corcept Therapeutics Inc. | New | 0.12% | +0.12 |
| ANL Adlai Nortye Group Ltd. | New | 0.07% | +0.07 |
| ALEC Alector Inc. | New | 0.06% | +0.06 |
| OKUR Onkure Therapeutics Inc. Class A | New | 0.06% | +0.06 |
| IBIO Ibio Inc. | Add +51.0% | 0.35% | +0.06 |
| LENZ Lenz Therapeutics Inc. | New | 0.05% | +0.05 |
| MGNX Macrogenics Inc. | Add +3.2% | 0.09% | +0.03 |
| AVBP Arrivent Biopharma Inc. | Add +16.7% | 0.24% | +0.02 |
| AVTX Avalo Therapeutics Inc. | Add +27.6% | 1.20% | −0.22 |
| FBRX Forte Biosciences Inc. | Add +2.3% | 1.57% | −0.43 |
| APGE Apogee Therapeutics Inc. | Add +4.0% | 6.47% | −0.44 |
| LXEO Lexeo Therapeutics Inc. | Add +57.8% | 1.73% | −0.62 |
| MLYS Mineralys Therapeutics Inc. | Add +2.7% | 1.22% | −0.75 |
| INSM Insmed Inc. | Add +6.7% | 4.70% | −1.11 |
Options Activity Q4 2025 → Q1 2026
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 1,500,000 | $182.9Mbefore exit |
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 200,000 | $130.1M |
| IBB iShares Biotechnology ETF | call | Sold out | 400,000 | $67.5Mbefore exit |
| AMGN Amgen Inc. | call | Sold out | 135,000 | $44.2Mbefore exit |
| MRNA Moderna Inc. | call | New | 800,000 | $40.6M |
| XLV SS Health Care Select Sector | call | Sold out | 250,000 | $38.7Mbefore exit |
| BMY Bristol-Myers Squibb Co. | call | New | 300,000 | $18.2M |
| RVMD Revolution Medicines Inc. | put | New | 100,000 | $9.7M |
| IBRX Immunitybio Inc. | put | New | 1,250,000 | $9.6M |
| NVO Novo-Nordisk A/S-Spons ADR | call | New | 175,000 | $6.4M |
| SMMT Summit Therapeutics Inc. | put | Sold out | 350,000 | $6.1Mbefore exit |
| QURE Uniqure NV | call | Reduce -62.5% | 300,000 | $4.9M |
| DNTH Dianthus Therapeutics Inc. | call | New | 50,000 | $4.2M |
| CGON CG Oncology Inc. | call | New | 60,000 | $4.1M |
| CELC Celcuity Inc. | call | New | 30,000 | $3.4M |
| ABUS Arbutus Biopharma Corp. | call | Sold out | 521,900 | $2.5Mbefore exit |
| LENZ Lenz Therapeutics Inc. | put | Sold out | 100,000 | $1.6Mbefore exit |
| FBRX Forte Biosciences Inc. | call | Sold out | 22,400 | $611Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2025 → Q1 2026
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | Sold out | 7,000,000 | $10.0Mbefore exit |
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | Add +600.0% | 7,000,000 | $8.6M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |